BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $9,391 | +874.2% | 1,126 | +1240.5% | 0.00% | – |
| Q4 2022 | $964 | -3.6% | 84 | -24.3% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 111 | +32.1% | 0.00% | – |
| Q2 2022 | $1,000 | -99.5% | 84 | -99.3% | 0.00% | – |
| Q1 2022 | $197,000 | +22.4% | 12,100 | +4.3% | 0.00% | – |
| Q4 2021 | $161,000 | +30.9% | 11,600 | +35.0% | 0.00% | – |
| Q3 2021 | $123,000 | -7.5% | 8,594 | +2.3% | 0.00% | – |
| Q2 2021 | $133,000 | +14.7% | 8,400 | -26.3% | 0.00% | – |
| Q1 2021 | $116,000 | +673.3% | 11,400 | +470.0% | 0.00% | – |
| Q4 2020 | $15,000 | +200.0% | 2,000 | +100.0% | 0.00% | – |
| Q2 2020 | $5,000 | -61.5% | 1,000 | -78.5% | 0.00% | – |
| Q3 2019 | $13,000 | -27.8% | 4,648 | 0.0% | 0.00% | – |
| Q2 2019 | $18,000 | +500.0% | 4,648 | +1243.4% | 0.00% | – |
| Q1 2019 | $3,000 | 0.0% | 346 | -9.9% | 0.00% | – |
| Q1 2015 | $3,000 | -40.0% | 384 | 0.0% | 0.00% | – |
| Q4 2014 | $5,000 | +25.0% | 384 | 0.0% | 0.00% | – |
| Q3 2014 | $4,000 | – | 384 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |